Lab21, Quidel Expand International Distribution Agreement
News Feb 11, 2014
Lab21 has expanded its existing agreement with Quidel Corporation, through its subsidiary, Microgen Bioproducts Limited. This expands on the previous agreement which has seen Lab21 distribute the QuickVue product range in the UK.
The AnDiaTec product range includes tests that aid in the diagnosis of several infectious diseases including Norovirus, Enterovirus, Epstein Barr Virus, Herpes Simplex, Varicella-Zoster Virus, Chlamydia and Mycobacterium tuberculosis. The previous agreement saw Lab21 distribute Quidel’s QuickVue products which included rapid diagnostics for Chlamydia, H. Pylori, Influenza, Respiratory Syncytial Virus, Streptococcus, and Pregnancy.
Graham Mullis, CEO of Lab21, commented: “We are delighted to expand our distribution partnership with Quidel to include the AnDiaTec molecular product portfolio. Having built a strong reputation in the provision of tests for infectious diseases, this deal will further expand the range of products we are able to offer, strengthening our position as experts in the provision of clinical diagnostics.”
John Garland, Senior Sales & Marketing Director EMEA, Quidel, commented: “Lab21 has a strong reputation in the provision of excellent clinical diagnostics products. Lab21’s expertise and network with its customer base will be crucial to encouraging the increased uptake of the rapid, accurate and easy to use AnDiaTec Product Range.”
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE